Citius Oncology (CTOR) Expected to Announce Earnings on Tuesday

Key Points

• Citius Oncology is expected to report Q3 2026 results before the market opens Tuesday, August 18. Analysts forecast a loss of $0.04 per share and revenue of approximately $5.83 million; the earnings call is scheduled for August 21.
• The company’s previous quarter fell well short of expectations, reporting a $0.27-per-share loss versus the projected $0.01 loss and revenue of $1.67 million versus the $7.00 million estimate.
• CTOR shares recently traded at $0.74, with a market capitalization of about $68.6 million. Analysts have an overall “Hold” rating and a $6.00 average price target, while institutional investors own 70.52% of the stock.

Citius Oncology (NASDAQ:CTOR - Get Free Report) is projected to post its Q3 2026 results before the market opens on Tuesday, August 18th. Analysts expect the company to post earnings of ($0.04) per share and revenue of $5.8310 million for the quarter. Interested persons may visit the the company's upcoming Q3 2026 earning report for the latest details on the call scheduled for Friday, August 21, 2026 at 4:00 PM ET.

Citius Oncology (NASDAQ:CTOR - Get Free Report) last issued its quarterly earnings results on Friday, May 15th. The company reported ($0.27) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.01) by ($0.26). The business had revenue of $1.67 million for the quarter, compared to analyst estimates of $7.00 million.

Citius Oncology Trading Down 2.1%

NASDAQ CTOR opened at $0.74 on Tuesday. The company has a fifty day simple moving average of $0.68 and a two-hundred day simple moving average of $0.83. The stock has a market cap of $68.57 million, a P/E ratio of -1.57 and a beta of 3.48. Citius Oncology has a 12-month low of $0.49 and a 12-month high of $2.25. The company has a current ratio of 0.50, a quick ratio of 0.12 and a debt-to-equity ratio of 0.11.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings raised Citius Oncology from a "sell (e+)" rating to a "sell (d-)" rating in a research report on Tuesday, July 28th. Two research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat, the company has an average rating of "Hold" and an average price target of $6.00.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the business. Citadel Advisors LLC acquired a new position in Citius Oncology during the third quarter valued at $36,000. Bank of America Corp DE boosted its holdings in Citius Oncology by 5,256.9% in the second quarter. Bank of America Corp DE now owns 8,571 shares of the company's stock valued at $37,000 after purchasing an additional 8,411 shares during the last quarter. OMERS ADMINISTRATION Corp acquired a new stake in Citius Oncology during the 4th quarter worth about $104,000. Geode Capital Management LLC grew its position in Citius Oncology by 31.6% during the 4th quarter. Geode Capital Management LLC now owns 220,047 shares of the company's stock worth $220,000 after purchasing an additional 52,875 shares during the period. Finally, Jane Street Group LLC acquired a new stake in Citius Oncology during the 2nd quarter worth about $465,000. Hedge funds and other institutional investors own 70.52% of the company's stock.

About Citius Oncology

Citius Oncology, Inc is a pharmaceutical company, which engages in developing and commercializing targeted oncology therapies. Its lead product candidate is LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein, for the treatment of patients with persistent or recurrent CTCL, a rare form of non-Hodgkin lymphoma. The company was founded on March 1, 2021 and is headquartered in Cranford, NJ.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source